Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals is at an inflection point ... market for drugs that treat the underlying causes of cystic fibrosis (CF), a rare disease that affects patients' organs. Plenty of drugmakers ...

Vertex Pharmaceuticals (VRTX ... its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...